Franklin Biotechnology Discovery Fund

Scorecard
4 / 5 Stars
Lipper
---
Zacks Investment Research
---
Standard & Poor's
1 / 5 Stars
TheStreet.com
C+ (Hold)

U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Franklin Templeton Investments funds

See full Health rankings

See more fund rankings

Performance

The fund has returned 81.99 percent over the past year, 41.77 percent over the past three years, 31.75 percent over the past five years, and 14.31 percent over the past decade.

Trailing Returns Updated 02.28.2014
Year to date 19.5%
1 Year 82.0%
3 Years (Annualized) 41.8%
5 Years (Annualized) 31.8%
10 Years (Annualized) 14.3%

See more FRBRX performance

Summary

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

See Also:

Top Franklin Templeton Investments Funds